Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Alisertib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA known ✓ | O14965 | 7/20 | 1.00 |
| ▸ | AURKB | Q96GD4 | 4/20 | 1.00 |
| ▸ | KDR | P35968 | 4/20 | 1.00 |
| ▸ | GABRA1 | P14867 | 3/20 | 1.00 |
| ▸ | PLK4 | O00444 | 2/20 | 1.00 |
| ▸ | PDPK1 | O15530 | 2/20 | 1.00 |
| ▸ | ABL1 | P00519 | 2/20 | 1.00 |
| ▸ | EGFR | P00533 | 2/20 | 1.00 |
| ▸ | LCK | P06239 | 2/20 | 1.00 |
| ▸ | HCK | P08631 | 2/20 | 1.00 |
| ▸ | ROS1 | P08922 | 2/20 | 1.00 |
| ▸ | FGFR1 | P11362 | 2/20 | 1.00 |
| ▸ | SRC | P12931 | 2/20 | 1.00 |
| ▸ | FER | P16591 | 2/20 | 1.00 |
| ▸ | FLT1 | P17948 | 2/20 | 1.00 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 1.00 |
| ▸ | FGFR3 | P22607 | 2/20 | 1.00 |
| ▸ | EPHA2 | P29317 | 2/20 | 1.00 |
| ▸ | GRK5 | P34947 | 2/20 | 1.00 |
| ▸ | ABL2 | P42684 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alisertib SCHEMBL29354333 | 1.00 | AURKA (1.00) | AURKAAURKBKDRGABRA1PLK4 | |
| Alisertib SCHEMBL29437869 | 1.00 | AURKA (1.00) | AURKAAURKBKDRGABRA1PLK4 | |
| Alisertib SCHEMBL29720486 | 1.00 | AURKA (1.00) | AURKAAURKBKDRGABRA1PLK4 | |
| Alisertib SCHEMBL29750414 | 1.00 | AURKA (1.00) | AURKAAURKBKDRGABRA1PLK4 | |
| Alisertib SCHEMBL15263514 | 0.99 | AURKA (0.98) | AURKAAURKBKDRGABRA1PLK4 | |
| Alisertib SCHEMBL854553 | 0.99 | AURKA (0.98) | AURKAAURKBKDRGABRA1PLK4 | |
| Alisertib SCHEMBL14125416 | 0.98 | AURKA (0.97) | AURKAAURKBKDRGABRA1PLK4 | |
| SCHEMBL2389378 | 0.97 | AURKA (0.94) | AURKAAURKBKDRGABRA1PLK4 | |
| SCHEMBL2389355 | 0.94 | AURKA (0.89) | AURKAAURKBKDRGABRA1PLK4 | |
| SCHEMBL20214913 | 0.94 | AURKA (0.89) | AURKAAURKBKDRGABRA1PLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 266 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250064824-A1 | ADMINISTRATION OF AURORA KINASE INHIBITOR AND CHEMOTHERAPEUTIC AGENTS | MILLENNIUM PHARM INC (US) | 2025-02-27 | — | — | US | claimed |
| US-12042499-B2 | Administration of aurora kinase inhibitor and chemotherapeutic agents | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2024-07-23 | — | — | US | claimed |
| US-11331272-B2 | Hyperstabilized liposomes increase targeting of mitotic cells | TEMASEK LIFE SCIENCES LABORATORY LIMITED (SG) | 2022-05-17 | — | — | US | claimed |
| EP-2432456-B1 | SOLID PHARMACEUTICAL COMPOSITIONS AND PROCESSES FOR THEIR PRODUCTION | MILLENNIUM PHARM INC (US) | 2021-12-29 | — | — | EP | claimed |
| US-20210213037-A1 | METHODS FOR TREATING FIBROSIS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2021-07-15 | — | — | US | claimed |
| EP-2713727-B1 | COMBINATION OF MEK INHIBITORS AND SELECTIVE INHIBITORS OF AURORA A KINASE | MILLENNIUM PHARM INC (US) | 2021-03-31 | — | — | EP | claimed |
| US-20200397799-A1 | ADMINISTRATION OF AURORA KINASE INHIBITOR AND CHEMOTHERAPEUTIC AGENTS | MILLENNIUM PHARMACEUTICALS, INC. | 2020-12-24 | — | — | US | claimed |
| EP-3317427-B1 | BIOMARKERS OF RESPONSE TO SELECTIVE INHIBITORS OF AURORA A KINASE | MILLENNIUM PHARM INC (US) | 2020-12-23 | — | — | EP | claimed |
| EP-3752161-A1 | METHODS FOR TREATING FIBROSIS | Children's Hospital Medical Center (US) | 2020-12-23 | — | — | EP | claimed |
| EP-2976086-B1 | COMBINATION OF CATALYTIC MTORC 1/2 INHIBITORS AND SELECTIVE INHIBITORS OF AURORA A KINASE | MILLENNIUM PHARM INC (US) | 2020-10-14 | — | — | EP | claimed |
| WO-2013083098-A2 | METHOD OF DETERMINATION OF CANCER CELL DRUG SENSITIVITY TOWARDS AURORA KINASE INHIBITORS | PALACKY UNIVERSITY, OLOMOUC (CZ) | 2013-06-13 | — | — | WO | claimed |
| EP-2602330-A1 | Method of determination of cancer cell drug sensitivity towards Aurora kinase inhibitors and overcoming their resistance | Palacky University, Olomouc (CZ) | 2013-06-12 | — | — | EP | claimed |
| EP-2497772-A1 | Compound for inhibiting mitotic progression | Millennium Pharmaceuticals, Inc. (US) | 2012-09-12 | — | — | EP | claimed |
| EP-2086981-B1 | COMPOUNDS FOR INHIBITING MITOTIC PROGRESSION | MILLENNIUM PHARM INC (US) | 2012-05-02 | — | — | EP | claimed |
| US-20110312943-A1 | AURORA KINASE INHIBITORS FOR INHIBITING MITOTIC PROGRESSION | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-12-22 | — | — | US | claimed |
| US-8026246-B2 | Anticancer agents; for breasts, ovaries,, prostate gland cancer; kinase inhibitors | Millennium Pharmaceuticials, Inc. (US) | 2011-09-27 | — | — | US | claimed |
| US-20100183601-A1 | Combination of Aurora Kinase Inhibitors and Anti-CD20 Antibodies | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-07-22 | — | — | US | claimed |
| EP-2086981-A1 | COMPOUNDS FOR INHIBITING MITOTIC PROGRESSION | Millennium Pharmaceuticals, Inc. (US) | 2009-08-12 | — | — | EP | claimed |
| US-20080167292-A1 | Compounds for inhibiting mitotic progression | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-07-10 | — | — | US | claimed |
| WO-2008063525-A1 | COMPOUNDS FOR INHIBITING MITOTIC PROGRESSION | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-05-29 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200397799-A1 | ADMINISTRATION OF AURORA KINASE INHIBITOR AND CHEMOTHERAPEUTIC AGENTS | AURKB, AURKA, AURKC | AURKA 2/4885AURKB 1/4885KDR 3873/4885 |
| US-20080167292-A1 | Compounds for inhibiting mitotic progression | AURKC, AURKA, AURKB | AURKA 2/4885AURKB 3/4885KDR 3573/4885 |
| US-20250064824-A1 | ADMINISTRATION OF AURORA KINASE INHIBITOR AND CHEMOTHERAPEUTIC AGENTS | AURKB, AURKA, AURKC | AURKA 2/4885AURKB 1/4885KDR 3873/4885 |
| US-20100183601-A1 | Combination of Aurora Kinase Inhibitors and Anti-CD20 Antibodies | AURKC, AURKB, AURKA | AURKA 3/4885AURKB 2/4885KDR 971/4885 |
| US-12042499-B2 | Administration of aurora kinase inhibitor and chemotherapeutic agents | AURKB, AURKA, AURKC | AURKA 2/4885AURKB 1/4885KDR 3873/4885 |
| US-20110312943-A1 | AURORA KINASE INHIBITORS FOR INHIBITING MITOTIC PROGRESSION | AURKC, AURKA, AURKB | AURKA 2/4885AURKB 3/4885KDR 2988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.